https://www.biopharmawatch.com/news/RVMD/revolution-medicines-excellence-client-partnership-award BiopharmaWatch en 2026-10-30T16:00:00.000Z Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award" https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-announces-1-4-reverse-stock-split BiopharmaWatch en 2026-10-30T14:30:00.000Z Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-avlayah-prix-galien-award BiopharmaWatch en 2026-10-30T13:30:00.000Z Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product https://www.biopharmawatch.com/news/NTHI/neonc-brain-cancer-plans-pivotal-trial BiopharmaWatch en 2026-10-30T13:10:00.000Z NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-castle-creek-merger BiopharmaWatch en 2026-10-30T13:09:00.000Z Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-rna-splicing-adc-payload-strategy BiopharmaWatch en 2026-10-30T13:05:00.000Z Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit https://www.biopharmawatch.com/news/SNDX/syndax-revuforj-prix-galien-award-2026 BiopharmaWatch en 2026-10-30T13:01:00.000Z Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases https://www.biopharmawatch.com/news/ALPS/alps-group-shareholder-approval-consolidation-capital-increase BiopharmaWatch en 2026-10-30T13:00:00.000Z Alps Group Inc Announces Shareholder Approval for a Share Consolidation, Share Capital Increase, and Adoption of Second Amended and Restated Memorandum and Articles of Association https://www.biopharmawatch.com/news/BGLC/bionexus-launches-new-corporate-website BiopharmaWatch en 2026-10-30T13:00:00.000Z BioNexus Launches New Corporate Website with Expanded Business and Investor Resources https://www.biopharmawatch.com/news/FEMY/femasys-appoints-john-moorhead-board-directors BiopharmaWatch en 2026-10-30T13:00:00.000Z Femasys Appoints John Moorhead to Board of Directors https://www.biopharmawatch.com/news/VTRS/viatris-tender-offer-acquire-pacira-biosciences BiopharmaWatch en 2026-10-30T12:40:00.000Z Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc. https://www.biopharmawatch.com/news/MBRX/moleculin-completes-dosing-miracle-trial BiopharmaWatch en 2026-10-30T12:40:00.000Z Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027 https://www.biopharmawatch.com/news/DARE/dare-bioscience-grant-funding-dare-larc1-development BiopharmaWatch en 2026-10-30T12:32:00.000Z Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum https://www.biopharmawatch.com/news/CDT/cdt-equity-hhs-regulatory-development-peptides BiopharmaWatch en 2026-10-30T12:32:00.000Z CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides https://www.biopharmawatch.com/news/NVNO/envveno-medical-q3-2026-financial-results-tavve-study BiopharmaWatch en 2026-10-30T12:30:00.000Z enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal Study https://www.biopharmawatch.com/news/PAVM/pavmed-business-update-conference-call-november-2026 BiopharmaWatch en 2026-10-30T12:30:00.000Z PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026 https://www.biopharmawatch.com/news/NBIX/neurocrine-educational-resources-classic-cah BiopharmaWatch en 2026-10-30T12:30:00.000Z Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-phase-1b-study-advanced-cancer BiopharmaWatch en 2026-10-30T12:30:00.000Z Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients https://www.biopharmawatch.com/news/IRMD/iradimed-corporation-reports-q3-2026-results BiopharmaWatch en 2026-10-30T12:30:00.000Z IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IART/integra-lifesciences-cns-2026-annual-meeting BiopharmaWatch en 2026-10-30T12:30:00.000Z Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-sitc-2026-presentation BiopharmaWatch en 2026-10-30T12:30:00.000Z Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting https://www.biopharmawatch.com/news/OGN/organon-announces-quarterly-dividend-20261030 BiopharmaWatch en 2026-10-30T12:25:00.000Z Organon Announces Quarterly Dividend https://www.biopharmawatch.com/news/STXS/canon-stereotaxis-robotic-electrophysiology-collaboration BiopharmaWatch en 2026-10-30T12:03:00.000Z Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology https://www.biopharmawatch.com/news/VOR/vor-bio-reports-q3-2026-results BiopharmaWatch en 2026-10-30T12:00:09.000Z Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/AUPH/aurinia-pharmaceuticals-financial-results-september-2026 BiopharmaWatch en 2026-10-30T12:00:00.000Z Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress https://www.biopharmawatch.com/news/PROF/profound-medical-cook-medical-partnership-tulsa-pro BiopharmaWatch en 2026-10-30T12:00:00.000Z Profound Medical and Cook Medical’s iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-q3-2026-results BiopharmaWatch en 2026-10-30T12:00:00.000Z Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/VBIO/valion-bio-entolimod-therapeutic-efficacy-study BiopharmaWatch en 2026-10-30T11:50:00.000Z Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results https://www.biopharmawatch.com/news/ABBV/abbvie-reports-q3-2026-financial-results BiopharmaWatch en 2026-10-30T11:46:00.000Z AbbVie Reports Third-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-first-commercial-agreement-clia-strategy BiopharmaWatch en 2026-10-30T11:45:00.000Z Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue https://www.biopharmawatch.com/news/OABI/omniab-reports-q3-2026-results BiopharmaWatch en 2026-10-30T11:40:00.000Z OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/IMNM/immunome-ema-validation-varegacestat-desmoid-tumors BiopharmaWatch en 2026-10-30T11:30:00.000Z Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors https://www.biopharmawatch.com/news/BRVE/braveheart-bio-aha-scientific-sessions-2026 BiopharmaWatch en 2026-10-30T11:30:00.000Z Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/BRVE/braveheart-bio-webinar-hcm-spotlight-november-2026 BiopharmaWatch en 2026-10-30T11:30:00.000Z Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026 https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-q1-fy27-update BiopharmaWatch en 2026-10-30T11:05:00.000Z Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Update https://www.biopharmawatch.com/news/ALKS/alkermes-phase-2-study-alks-7290-mdd BiopharmaWatch en 2026-10-30T11:00:00.000Z Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD) https://www.biopharmawatch.com/news/AZN/astrazeneca-results-9m-q3-2026 BiopharmaWatch en 2026-10-30T11:00:00.000Z AstraZeneca results: 9M and Q3 2026 https://www.biopharmawatch.com/news/AGIO/agios-mitapivat-pdufa-extension-february-2027 BiopharmaWatch en 2026-10-30T11:00:00.000Z Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA https://www.biopharmawatch.com/news/GUTS/fractyl-health-revita-patent-portfolio-fda-submission BiopharmaWatch en 2026-10-30T11:00:00.000Z Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-approval-preservative-free-ketamine BiopharmaWatch en 2026-10-30T11:00:00.000Z NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-altitude-ad-trial-results BiopharmaWatch en 2026-10-30T11:00:00.000Z Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint https://www.biopharmawatch.com/news/SNDX/syndax-announces-participation-november-investor-conferences BiopharmaWatch en 2026-10-30T11:00:00.000Z Syndax Announces Participation in November Investor Conferences https://www.biopharmawatch.com/news/REGN/regeneron-reports-q3-2026-results BiopharmaWatch en 2026-10-30T10:30:00.000Z Regeneron Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261030 BiopharmaWatch en 2026-10-30T10:00:00.000Z IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-investor-conferences-2026 BiopharmaWatch en 2026-10-30T10:00:00.000Z Kestra Medical Technologies to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-inc-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-30T10:00:00.000Z BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance https://www.biopharmawatch.com/news/RGEN/repligen-announces-1-billion-convertible-notes-transaction BiopharmaWatch en 2026-10-30T10:00:00.000Z Repligen Announces $1 Billion Private Convertible Senior Notes Transaction https://www.biopharmawatch.com/news/EVAX/evaxion-prix-galien-award-ai-immunology BiopharmaWatch en 2026-10-30T08:00:00.000Z Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution https://www.biopharmawatch.com/news/SNY/sanofi-q3-2026-sales-growth-guidance-upgraded BiopharmaWatch en 2026-10-30T06:30:00.000Z Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded https://www.biopharmawatch.com/news/SIBN/si-bone-presents-ubs-global-healthcare-conference-2026 BiopharmaWatch en 2026-10-29T21:43:00.000Z SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026 https://www.biopharmawatch.com/news/TLX/telix-general-meeting-acquisition-itm BiopharmaWatch en 2026-10-29T21:15:30.000Z Telix Notice of General Meeting, Proxy Form and Online Guide https://www.biopharmawatch.com/news/TMDX/transmedics-upcoming-investor-conferences BiopharmaWatch en 2026-10-29T21:01:00.000Z TransMedics to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-mavorixafor-clinical-progress BiopharmaWatch en 2026-10-29T20:30:31.000Z X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day https://www.biopharmawatch.com/news/BIO/bio-rad-fireside-chat-ubs-global-healthcare-conference BiopharmaWatch en 2026-10-29T20:30:00.000Z Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference https://www.biopharmawatch.com/news/NEPH/nephros-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-29T20:30:00.000Z Nephros Schedules Third Quarter 2026 Financial Results Conference Call https://www.biopharmawatch.com/news/TARS/tarsus-report-q3-2026-financial-results BiopharmaWatch en 2026-10-29T20:30:00.000Z Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-participate-upcoming-investor-conferences BiopharmaWatch en 2026-10-29T20:30:00.000Z Cytek Biosciences to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/SEER/seer-remains-independent-after-review-process BiopharmaWatch en 2026-10-29T20:30:00.000Z Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process https://www.biopharmawatch.com/news/SDEV/stablecoin-development-corporation-q3-2026-results BiopharmaWatch en 2026-10-29T20:21:00.000Z Stablecoin Development Corporation Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/A/agilent-fourth-quarter-fiscal-year-2026-results BiopharmaWatch en 2026-10-29T20:15:00.000Z Agilent to Announce Fourth-Quarter Fiscal Year 2026 Financial Results on Nov. 23 https://www.biopharmawatch.com/news/DRMA/dermata-tome-clearing-treatment-acne-trial-2027-launch BiopharmaWatch en 2026-10-29T20:05:00.000Z Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical Trial https://www.biopharmawatch.com/news/PRTA/prothena-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-29T20:05:00.000Z Prothena to Report Third Quarter 2026 Financial Results on November 5 https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-participate-canaccord-forum BiopharmaWatch en 2026-10-29T20:05:00.000Z TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum https://www.biopharmawatch.com/news/ATEC/atec-reports-third-quarter-financial-results BiopharmaWatch en 2026-10-29T20:05:00.000Z ATEC Reports Third Quarter Financial Results https://www.biopharmawatch.com/news/NPCE/neuropace-q3-2026-financial-results BiopharmaWatch en 2026-10-29T20:05:00.000Z NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-stifel-2026-healthcare-conference BiopharmaWatch en 2026-10-29T20:05:00.000Z Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-q3-2026-results-conference-call BiopharmaWatch en 2026-10-29T20:05:00.000Z Sensus Healthcare to Report Third Quarter 2026 Financial Results and Hold Business Update Conference Call on November 12, 2026 https://www.biopharmawatch.com/news/EXEL/exelixis-q3-2026-financial-results-update BiopharmaWatch en 2026-10-29T20:05:00.000Z Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/MMSI/merit-medical-reports-q3-2026-results BiopharmaWatch en 2026-10-29T20:05:00.000Z Merit Medical Reports Third Quarter 2026 Results: Delivers 9% Organic Constant Currency Revenue Growth and Raises Full-Year 2026 Guidance https://www.biopharmawatch.com/news/CV/capsovision-q3-2026-financial-results-release BiopharmaWatch en 2026-10-29T20:05:00.000Z CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-presentations-sitc-2026 BiopharmaWatch en 2026-10-29T20:05:00.000Z Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer https://www.biopharmawatch.com/news/IMRX/immuneering-reports-q3-2026-results-and-updates BiopharmaWatch en 2026-10-29T20:05:00.000Z Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/SYK/stryker-reports-q3-2026-results BiopharmaWatch en 2026-10-29T20:05:00.000Z Stryker reports third quarter 2026 operating results https://www.biopharmawatch.com/news/BSEM/biostem-technologies-q3-2026-financial-results-call BiopharmaWatch en 2026-10-29T20:05:00.000Z BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026 https://www.biopharmawatch.com/news/PEN/penumbra-reports-q3-2026-financial-results BiopharmaWatch en 2026-10-29T20:05:00.000Z Penumbra, Inc. Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ILMN/illumina-reports-q3-2026-financial-results BiopharmaWatch en 2026-10-29T20:05:00.000Z Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026 https://www.biopharmawatch.com/news/RMD/resmed-q1-fiscal-year-2027-results BiopharmaWatch en 2026-10-29T20:05:00.000Z Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027 https://www.biopharmawatch.com/news/SUPN/supernus-announces-third-quarter-2026-results BiopharmaWatch en 2026-10-29T20:05:00.000Z Supernus Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DXCM/dexcom-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-29T20:03:00.000Z Dexcom Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GILD/gilead-sciences-announces-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-29T20:02:00.000Z Gilead Sciences Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BHVN/biohaven-reports-business-developments-q3-2026 BiopharmaWatch en 2026-10-29T20:02:00.000Z Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BBIO/bridgebio-reports-q3-2026-results BiopharmaWatch en 2026-10-29T20:01:00.000Z BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates https://www.biopharmawatch.com/news/CDNA/caredx-q3-2026-financial-results BiopharmaWatch en 2026-10-29T20:01:00.000Z CareDx Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-q3-2026-financial-results-webcast BiopharmaWatch en 2026-10-29T20:01:00.000Z Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-q3-2026-results BiopharmaWatch en 2026-10-29T20:01:00.000Z Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-november-2026-investor-conference-schedule BiopharmaWatch en 2026-10-29T20:01:00.000Z Maravai LifeSciences Announces November 2026 Investor Conference Schedule https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-q3-2026-update BiopharmaWatch en 2026-10-29T20:01:00.000Z PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MNKD/mannkind-third-quarter-financial-results-november-2026 BiopharmaWatch en 2026-10-29T20:01:00.000Z MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-reports-q3-2026-results BiopharmaWatch en 2026-10-29T20:01:00.000Z Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year Outlook https://www.biopharmawatch.com/news/PDEX/pro-dex-fiscal-2027-first-quarter-results BiopharmaWatch en 2026-10-29T20:00:00.000Z Pro-Dex, Inc. Announces Fiscal 2027 First Quarter Results https://www.biopharmawatch.com/news/MDXH/mdxhealth-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-29T20:00:00.000Z Mdxhealth to Release Third Quarter 2026 Financial Results on November 12 https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-phase-2-abi-6250-hdv BiopharmaWatch en 2026-10-29T20:00:00.000Z Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-conference-call-regulatory-milestone BiopharmaWatch en 2026-10-29T20:00:00.000Z NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine https://www.biopharmawatch.com/news/QDEL/transforming-data-into-actionable-insights-lab BiopharmaWatch en 2026-10-29T19:27:00.000Z Transforming Data Into Actionable Insights in the Lab https://www.biopharmawatch.com/news/UFPT/ufp-technologies-third-quarter-results-november-2026 BiopharmaWatch en 2026-10-29T17:34:00.000Z UFP Technologies to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-stifel-2026-healthcare-conference BiopharmaWatch en 2026-10-29T17:05:00.000Z Pulse Biosciences to Present at Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/PRGO/perrigo-announces-quarterly-dividend-20261029 BiopharmaWatch en 2026-10-29T16:30:00.000Z Perrigo Announces Quarterly Dividend https://www.biopharmawatch.com/news/UTMD/utah-medical-products-corrected-results-tender-offer BiopharmaWatch en 2026-10-29T16:10:00.000Z Utah Medical Products, Inc. Reports Corrected Results of Tender Offer https://www.biopharmawatch.com/news/NRSN/neurosense-primec-phase-3-development-neals-2026 BiopharmaWatch en 2026-10-29T15:30:00.000Z NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026 https://www.biopharmawatch.com/news/PFE/edison-scientific-agreement-pfizer-rd BiopharmaWatch en 2026-10-29T15:00:00.000Z Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development https://www.biopharmawatch.com/news/VVOS/correction-sod-sciences-welcomes-vivos-therapeutics-strategic-investor-partner-rebalu BiopharmaWatch en 2026-10-29T14:52:00.000Z CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test https://www.biopharmawatch.com/news/NVAX/novavax-sanofi-phase-3-combination-vaccine-trial BiopharmaWatch en 2026-10-29T13:37:00.000Z Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe https://www.biopharmawatch.com/news/AIDX/2020-biolabs-investor-webinar-november-2026 BiopharmaWatch en 2026-10-29T13:37:00.000Z 20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth Strategy https://www.biopharmawatch.com/news/COSM/cosmos-health-us-active-subscriptions-surpass-12000 BiopharmaWatch en 2026-10-29T13:23:00.000Z Cosmos Health's U.S. Active Subscriptions Surpass 12,000, Up 92% in Two Weeks https://www.biopharmawatch.com/news/CODX/co-diagnostics-q3-2026-earnings-release-webcast BiopharmaWatch en 2026-10-29T13:15:00.000Z Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast https://www.biopharmawatch.com/news/INMB/inmune-bio-third-quarter-2026-update BiopharmaWatch en 2026-10-29T13:15:00.000Z INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th https://www.biopharmawatch.com/news/LFST/lifestance-treatment-resistant-depression-improvements BiopharmaWatch en 2026-10-29T13:00:00.000Z LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows https://www.biopharmawatch.com/news/PPBT/purple-biotech-im1240-oral-presentation-eortc-nci-aacr BiopharmaWatch en 2026-10-29T13:00:00.000Z Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium https://www.biopharmawatch.com/news/CELU/celularity-vesalius-collaboration-peptual-peptide-apis BiopharmaWatch en 2026-10-29T13:00:00.000Z Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States https://www.biopharmawatch.com/news/ABT/abbott-initiates-crown-mv-trial-cephea-device BiopharmaWatch en 2026-10-29T13:00:00.000Z Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease https://www.biopharmawatch.com/news/CODX/co-diagnostics-cosara-hpv-screening-study-publication BiopharmaWatch en 2026-10-29T13:00:00.000Z Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® Test https://www.biopharmawatch.com/news/PRGO/perrigo-divests-infant-formula-business-meridianmade BiopharmaWatch en 2026-10-29T13:00:00.000Z Perrigo Announces Agreement to Divest Infant Formula Business to MeridianMade https://www.biopharmawatch.com/news/ROIV/roivant-social-ventures-support-no-patient-left-behind BiopharmaWatch en 2026-10-29T13:00:00.000Z Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-phase-2-amplify-7p-results-sitc-2026 BiopharmaWatch en 2026-10-29T13:00:00.000Z Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-art27-13-pain-treatment-presentation BiopharmaWatch en 2026-10-29T13:00:00.000Z Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain https://www.biopharmawatch.com/news/XGN/exagen-inc-participate-investor-conferences BiopharmaWatch en 2026-10-29T13:00:00.000Z Exagen Inc. to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/CADL/candel-therapeutics-aglatimagene-sitc-2026-presentation BiopharmaWatch en 2026-10-29T13:00:00.000Z Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer https://www.biopharmawatch.com/news/IMCR/immunocore-phase-1-data-brenetafusp-kimmtrak-sitc-2026 BiopharmaWatch en 2026-10-29T13:00:00.000Z Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting https://www.biopharmawatch.com/news/BMRN/biomarin-exclusive-license-agreement-gc-biopharma-hanmi BiopharmaWatch en 2026-10-29T12:45:00.000Z BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease https://www.biopharmawatch.com/news/SABS/sab-bio-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-29T12:30:27.000Z SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET https://www.biopharmawatch.com/news/XENE/xen1120-phase-2-ready-kv7-channel-opener BiopharmaWatch en 2026-10-29T12:30:00.000Z XEN1120, a Phase 2-Ready KV7 Channel Opener: Advancing a Novel Non- Opioid Strategy for Pain https://www.biopharmawatch.com/news/XENE/xen1701-phase-2-ready-nav1-7-inhibitor BiopharmaWatch en 2026-10-29T12:30:00.000Z XEN1701, a Phase 2-Ready NaV1.7 Inhibitor: Advancing a Novel Non-Opioid Strategy for Pain https://www.biopharmawatch.com/news/UTMD/utah-medical-products-tender-offer-results BiopharmaWatch en 2026-10-29T12:30:00.000Z Utah Medical Products, Inc. Reports Results of Tender Offer https://www.biopharmawatch.com/news/HCA/hca-healthcare-hospitals-healthgrades-recognition BiopharmaWatch en 2026-10-29T12:30:00.000Z More Than 100 HCA Healthcare Hospitals Recognized by Healthgrades for Excellence in Specialty Care https://www.biopharmawatch.com/news/AZTR/azitra-expands-atr-04-trial-eligibility BiopharmaWatch en 2026-10-29T12:30:00.000Z Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-q3-2026-business-update-call BiopharmaWatch en 2026-10-29T12:30:00.000Z Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026 https://www.biopharmawatch.com/news/XENE/xenon-positive-phase-1-preclinical-data-iasp-2026 BiopharmaWatch en 2026-10-29T12:30:00.000Z Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-virtue-sab-tct-2026-presentation BiopharmaWatch en 2026-10-29T12:30:00.000Z Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026 https://www.biopharmawatch.com/news/CELC/celcuity-q3-2026-results-webcast-call BiopharmaWatch en 2026-10-29T12:30:00.000Z Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-third-quarter-2026-results BiopharmaWatch en 2026-10-29T12:30:00.000Z Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-corporate-update-q3-2026 BiopharmaWatch en 2026-10-29T12:30:00.000Z Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/MLSS/milestone-scientific-growth-update-compuflo-expansion BiopharmaWatch en 2026-10-29T12:30:00.000Z Milestone Scientific Provides Major Commercial Growth Update as CompuFlo® Expands Across 30 Million+ Annual Global Epidural Procedures https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-november-investor-events BiopharmaWatch en 2026-10-29T12:30:00.000Z Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data https://www.biopharmawatch.com/news/GH/guardant-health-new-law-colorectal-cancer-screening BiopharmaWatch en 2026-10-29T12:05:00.000Z Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians https://www.biopharmawatch.com/news/RIGL/rigel-conference-call-q3-2026-results BiopharmaWatch en 2026-10-29T12:05:00.000Z Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ACRV/acrivon-phase-1-2-acr-2316-eortc-nci-aacr-symposium BiopharmaWatch en 2026-10-29T12:00:50.000Z Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium https://www.biopharmawatch.com/news/TLRY/breckenridge-distillery-denver-hockey-whiskey-release BiopharmaWatch en 2026-10-29T12:00:38.000Z Breckenridge Distillery and University of Denver Athletics Release Limited-Edition Whiskey Celebrating Record 11th NCAA Men’s Hockey Championship https://www.biopharmawatch.com/news/RFL/rafael-holdings-fiscal-2026-results-update BiopharmaWatch en 2026-10-29T12:00:00.000Z Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ANVS/annovis-participate-us-biotech-day-pharma-partnering-summit-2026 BiopharmaWatch en 2026-10-29T12:00:00.000Z Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026 https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-early-lung-cancer-detection BiopharmaWatch en 2026-10-29T12:00:00.000Z bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month https://www.biopharmawatch.com/news/TWST/twist-bioscience-launches-mrd-express BiopharmaWatch en 2026-10-29T12:00:00.000Z Twist Bioscience Launches MRD Express with Rapid Turnaround Time https://www.biopharmawatch.com/news/NTRA/natera-third-quarter-results-november-2026 BiopharmaWatch en 2026-10-29T12:00:00.000Z Natera to Report its Third Quarter Results on November 5, 2026 https://www.biopharmawatch.com/news/LCTX/lineage-update-resonance-program-hearing-loss BiopharmaWatch en 2026-10-29T12:00:00.000Z Lineage Provides Update on ReSonance® Program for Hearing Loss https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-10-29T12:00:00.000Z Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress https://www.biopharmawatch.com/news/ESTA/establishment-labs-reports-q3-2026-results BiopharmaWatch en 2026-10-29T12:00:00.000Z Establishment Labs® Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ANGO/angiodynamics-participate-investor-conferences BiopharmaWatch en 2026-10-29T12:00:00.000Z AngioDynamics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/NVAX/novavax-q3-2026-financial-results-release BiopharmaWatch en 2026-10-29T12:00:00.000Z Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/MRK/merck-manuals-sunscreen-types BiopharmaWatch en 2026-10-29T12:00:00.000Z Merck Manuals Helps Patients Navigate the Different Types of Sunscreens https://www.biopharmawatch.com/news/NUVB/nuvation-bio-sigma-study-expansion-europe BiopharmaWatch en 2026-10-29T12:00:00.000Z Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries https://www.biopharmawatch.com/news/ELOX/eloxx-fda-clearance-exaluren-adpkd-trial BiopharmaWatch en 2026-10-29T12:00:00.000Z Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-q3-2026-results BiopharmaWatch en 2026-10-29T12:00:00.000Z CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/ECOR/electrocore-q3-2026-financial-results-announcement BiopharmaWatch en 2026-10-29T12:00:00.000Z electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026 https://www.biopharmawatch.com/news/PYPD/polypid-q3-2026-financial-results-report BiopharmaWatch en 2026-10-29T12:00:00.000Z PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026 https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-third-quarter-2026-results BiopharmaWatch en 2026-10-29T12:00:00.000Z Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights https://www.biopharmawatch.com/news/XAIR/beyond-air-conference-call-financial-results-q3-2026 BiopharmaWatch en 2026-10-29T12:00:00.000Z Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q3-2026-results BiopharmaWatch en 2026-10-29T12:00:00.000Z Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/ATYR/atyr-pharma-announces-publication-results-phase-3-efzo-fit-study BiopharmaWatch en 2026-10-29T12:00:00.000Z aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine https://www.biopharmawatch.com/news/MDWD/mediwound-report-q3-2026-results BiopharmaWatch en 2026-10-29T12:00:00.000Z MediWound to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q1-fy27 BiopharmaWatch en 2026-10-29T12:00:00.000Z Immutep Quarterly Activities Report Q1 FY27 https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-skny-1-obesity-study-results BiopharmaWatch en 2026-10-29T12:00:00.000Z MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide https://www.biopharmawatch.com/news/NTLA/intellia-lonvoguran-ziclumeran-investor-event-acaa-2026 BiopharmaWatch en 2026-10-29T12:00:00.000Z Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026 https://www.biopharmawatch.com/news/COLL/collegium-boston-legacy-partnership-neurodiversity BiopharmaWatch en 2026-10-29T12:00:00.000Z Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts https://www.biopharmawatch.com/news/SCYX/scynexis-participate-guggenheim-healthcare-conference BiopharmaWatch en 2026-10-29T12:00:00.000Z SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-corporate-pipeline-progress BiopharmaWatch en 2026-10-29T12:00:00.000Z Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics https://www.biopharmawatch.com/news/FEED/envue-medical-uroshield-production-uk-orders BiopharmaWatch en 2026-10-29T11:30:00.000Z ENvue Medical Commences U.S. Production of UroShield(R) and Begins Fulfilling UK Distributor Orders https://www.biopharmawatch.com/news/VRAX/virax-biolabs-distributors-immune-select-china BiopharmaWatch en 2026-10-29T11:30:00.000Z Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-intelligent-orthopedic-surgery-aahks-2026 BiopharmaWatch en 2026-10-29T11:30:00.000Z Zimmer Biomet to Preview the Next Era of Intelligent Orthopedic Surgery at AAHKS 2026 https://www.biopharmawatch.com/news/ADCT/adct-zynlonta-updates-japan BiopharmaWatch en 2026-10-29T11:30:00.000Z ADC Therapeutics Announces ZYNLONTA® Updates in Japan https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-10-29T11:30:00.000Z Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/SIGA/siga-business-update-call-november-2026 BiopharmaWatch en 2026-10-29T11:30:00.000Z SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CNSY/cerenome-completes-enrollment-phase-2-respect-gbm-trial BiopharmaWatch en 2026-10-29T11:30:00.000Z Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma https://www.biopharmawatch.com/news/CRVO/cervomed-announces-publication-two-peer-reviewed-research-articles-supporting-neflamapimod BiopharmaWatch en 2026-10-29T11:30:00.000Z CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB) https://www.biopharmawatch.com/news/DAVI/davion-healthcare-acquires-home-healthcare-business BiopharmaWatch en 2026-10-29T11:30:00.000Z Davion Healthcare PLC Agrees $13.5 Million Acquisition of Profitable US Home Healthcare Business https://www.biopharmawatch.com/news/BAX/baxter-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-29T11:15:00.000Z Baxter Reports Third-Quarter 2026 Results https://www.biopharmawatch.com/news/RGNX/regenxbio-conference-call-november-2026 BiopharmaWatch en 2026-10-29T11:05:00.000Z REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/OCGN/ocugen-participate-november-investor-conferences BiopharmaWatch en 2026-10-29T11:02:00.000Z Ocugen to Participate in Upcoming November Investor and Industry Conferences https://www.biopharmawatch.com/news/STAA/staar-surgical-appoints-pascal-aeschlimann-vp-asia-pacific BiopharmaWatch en 2026-10-29T11:01:00.000Z STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific https://www.biopharmawatch.com/news/DTIL/precision-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-10-29T11:01:00.000Z Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/RFL/rafael-holdings-nda-submission-remibetadex-npc BiopharmaWatch en 2026-10-29T11:00:00.000Z Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-kio-401-crao-naion-trial BiopharmaWatch en 2026-10-29T11:00:00.000Z Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan https://www.biopharmawatch.com/news/EYE/national-vision-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-29T11:00:00.000Z National Vision Holdings, Inc. Announces Third Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/ACB/aurora-cannabis-q2-2027-investor-call BiopharmaWatch en 2026-10-29T11:00:00.000Z Aurora Cannabis to Host Second Quarter 2027 Investor Conference Call https://www.biopharmawatch.com/news/BLCO/bausch-lomb-dry-eye-survey-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education https://www.biopharmawatch.com/news/INCY/incyte-reports-q3-2026-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/NVCR/novocure-q3-2026-financial-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-q3-2026-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CTSO/cytosorbents-q3-2026-financial-results-webcast BiopharmaWatch en 2026-10-29T11:00:00.000Z CytoSorbents to Report Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/INSM/insmed-reports-q3-2026-financial-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-guggenheim-conference-2026 BiopharmaWatch en 2026-10-29T11:00:00.000Z Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/INDV/indivior-reports-q3-2026-financial-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Indivior Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-november-conferences-2026 BiopharmaWatch en 2026-10-29T11:00:00.000Z Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences https://www.biopharmawatch.com/news/TLRY/tilray-brands-beverage-transformation-phase BiopharmaWatch en 2026-10-29T11:00:00.000Z Tilray Brands Announces Next Phase of Beverage Transformation https://www.biopharmawatch.com/news/IRD/opus-genetics-appoints-new-executives BiopharmaWatch en 2026-10-29T11:00:00.000Z Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-announces-participation-upcoming-investor-conference-inducement-grant BiopharmaWatch en 2026-10-29T11:00:00.000Z Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q3-2026-results-update BiopharmaWatch en 2026-10-29T11:00:00.000Z Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/IOVA/iova-iov-lun-202-results-precision-til-strategy BiopharmaWatch en 2026-10-29T11:00:00.000Z Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC) https://www.biopharmawatch.com/news/GUTS/fractyl-health-research-patient-interest-weight-maintenance BiopharmaWatch en 2026-10-29T11:00:00.000Z Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance https://www.biopharmawatch.com/news/BCRX/biocryst-presents-new-data-orladeyo-navenibart-acaa-2026 BiopharmaWatch en 2026-10-29T11:00:00.000Z BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-expansion-discovery-platform BiopharmaWatch en 2026-10-29T11:00:00.000Z C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders https://www.biopharmawatch.com/news/LGND/ligand-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-29T11:00:00.000Z Ligand Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-participate-2026-jefferies-global-healthcare-conference-london BiopharmaWatch en 2026-10-29T11:00:00.000Z Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-q3-2026-results-kt-579-trial BiopharmaWatch en 2026-10-29T11:00:00.000Z Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-q3-2026-results BiopharmaWatch en 2026-10-29T10:59:00.000Z Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 https://www.biopharmawatch.com/news/BIIB/biogen-new-data-alzheimers-ctad-2026 BiopharmaWatch en 2026-10-29T10:59:00.000Z Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026 https://www.biopharmawatch.com/news/PHVS/pharvaris-acaai-2026-annual-scientific-meeting BiopharmaWatch en 2026-10-29T10:50:00.000Z Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-q3-2026-financial-results BiopharmaWatch en 2026-10-29T10:50:00.000Z Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/LLY/lilly-q3-2026-financial-results-guidance-regulatory-progress BiopharmaWatch en 2026-10-29T10:45:00.000Z Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio https://www.biopharmawatch.com/news/THC/tenet-reports-strong-q3-2026-results BiopharmaWatch en 2026-10-29T10:45:00.000Z Tenet Reports Strong Third Quarter 2026 Results; Raises 2026 Financial Outlook https://www.biopharmawatch.com/news/BFLY/butterfly-network-q3-2026-results BiopharmaWatch en 2026-10-29T10:30:00.000Z Butterfly Network Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MRK/merck-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-29T10:30:00.000Z Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline https://www.biopharmawatch.com/news/HIT/health-in-tech-q3-2026-financial-results-announcement BiopharmaWatch en 2026-10-29T10:30:00.000Z Health In Tech to Announce Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/IMUX/immunic-virtual-rd-day-progressive-ms-november-2026 BiopharmaWatch en 2026-10-29T10:30:00.000Z Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026 https://www.biopharmawatch.com/news/FTRE/fortrea-reports-q3-2026-results BiopharmaWatch en 2026-10-29T10:30:00.000Z Fortrea Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/MD/pediatrix-medical-group-reports-third-quarter-results BiopharmaWatch en 2026-10-29T10:00:00.000Z Pediatrix Medical Group Reports Third Quarter Results https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-q3-2026-earnings-call BiopharmaWatch en 2026-10-29T10:00:00.000Z Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/WST/west-pharmaceutical-third-quarter-2026-results BiopharmaWatch en 2026-10-29T10:00:00.000Z West Reports Third-Quarter 2026 Results https://www.biopharmawatch.com/news/RDNT/radnet-q3-2026-financial-results-conference-call BiopharmaWatch en 2026-10-29T10:00:00.000Z RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call https://www.biopharmawatch.com/news/OCS/oculis-privosegtor-pioneer-program-apois-cns-summit BiopharmaWatch en 2026-10-29T09:10:00.000Z Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit https://www.biopharmawatch.com/news/PHG/philips-uniguide-3d-live-guidance-launch BiopharmaWatch en 2026-10-29T09:00:00.000Z Philips launches UniGuide 3D Live Guidance, bringing CT planning into live procedures and extending the capabilities of its Azurion image-guided therapy platform https://www.biopharmawatch.com/news/EVO/evotec-announces-results-november-2026 BiopharmaWatch en 2026-10-29T07:00:00.000Z Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026 https://www.biopharmawatch.com/news/TAK/takeda-fy2026-first-half-results-launch-momentum BiopharmaWatch en 2026-10-29T06:36:00.000Z Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones https://www.biopharmawatch.com/news/MOLN/molecular-partners-q3-2026-financial-results BiopharmaWatch en 2026-10-29T06:00:29.000Z Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy https://www.biopharmawatch.com/news/ADXN/addex-increases-issued-share-capital BiopharmaWatch en 2026-10-29T06:00:00.000Z ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES https://www.biopharmawatch.com/news/MESO/mesoblast-quarterly-report-september-2026 BiopharmaWatch en 2026-10-29T00:19:00.000Z Activity Report for Quarter Ended September 30, 2026 (Appendix 4C) https://www.biopharmawatch.com/news/CNTN/canton-strategic-holdings-tokenized-equity BiopharmaWatch en 2026-10-29T00:00:00.000Z Canton Strategic Holdings Announces Intent to Become First Tokenized U.S. Equity https://www.biopharmawatch.com/news/HCM/hutchmed-sovleplenib-fda-orphan-drug-designation-itp BiopharmaWatch en 2026-10-29T00:00:00.000Z HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia https://www.biopharmawatch.com/news/IOVA/iovance-webcast-positive-data-til-therapy-mnslc BiopharmaWatch en 2026-10-28T23:00:00.000Z Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy https://www.biopharmawatch.com/news/PRPO/precipio-q3-2026-shareholder-update-call BiopharmaWatch en 2026-10-28T21:00:00.000Z Precipio Announces Q3-2026 Shareholder Update Call https://www.biopharmawatch.com/news/DBVT/dbv-technologies-q3-2026-financial-results BiopharmaWatch en 2026-10-28T20:47:00.000Z DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/QTRX/quanterix-third-quarter-2026-results-call BiopharmaWatch en 2026-10-28T20:30:00.000Z Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-webcast-first-quarter-results BiopharmaWatch en 2026-10-28T20:30:00.000Z Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-strategic-process-ttx-mc138 BiopharmaWatch en 2026-10-28T20:30:00.000Z TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio https://www.biopharmawatch.com/news/AMGN/amgen-webcast-2026-q3-financial-results BiopharmaWatch en 2026-10-28T20:30:00.000Z AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS https://www.biopharmawatch.com/news/STE/steris-announces-dividend-0-69-per-share BiopharmaWatch en 2026-10-28T20:30:00.000Z STERIS Announces Dividend of $0.69 per share https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-q3-2026-results-reorganization-ceo-transition BiopharmaWatch en 2026-10-28T20:30:00.000Z LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession https://www.biopharmawatch.com/news/EHC/encompass-health-q3-2026-results BiopharmaWatch en 2026-10-28T20:24:25.943Z Encompass Health reports results for third quarter 2026 https://www.biopharmawatch.com/news/CYH/community-health-systems-q3-2026-results BiopharmaWatch en 2026-10-28T20:15:00.000Z Community Health Systems, Inc. Announces Third Quarter Ended September 30, 2026 Results https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-inducement-grants-october-2026 BiopharmaWatch en 2026-10-28T20:15:00.000Z Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q3-2026-results-announcement BiopharmaWatch en 2026-10-28T20:12:00.000Z Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026 https://www.biopharmawatch.com/news/AORT/artivion-participate-upcoming-investor-conferences-20261028 BiopharmaWatch en 2026-10-28T20:10:00.000Z Artivion to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/BHC/bausch-health-redemption-senior-notes-2027 BiopharmaWatch en 2026-10-28T20:07:00.000Z Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027 https://www.biopharmawatch.com/news/BHC/bausch-health-announces-share-repurchase-program BiopharmaWatch en 2026-10-28T20:06:00.000Z Bausch Health Announces US$50 Million Share Repurchase Program https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-reports-q3-2026-results BiopharmaWatch en 2026-10-28T20:05:00.000Z ClearPoint Neuro Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/ALGN/align-technology-ceo-succession-plan BiopharmaWatch en 2026-10-28T20:05:00.000Z Align Technology Announces CEO Succession Plan https://www.biopharmawatch.com/news/CNMD/conmed-reports-q3-2026-results-guidance-update BiopharmaWatch en 2026-10-28T20:05:00.000Z CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance https://www.biopharmawatch.com/news/ALGN/align-technology-q3-2026-financial-results BiopharmaWatch en 2026-10-28T20:05:00.000Z Align Technology Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GKOS/glaukos-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-28T20:05:00.000Z Glaukos Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-third-quarter-2026-update BiopharmaWatch en 2026-10-28T20:05:00.000Z Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-ubs-global-biopharma-conference-2026 BiopharmaWatch en 2026-10-28T20:05:00.000Z Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026 https://www.biopharmawatch.com/news/NEO/neogenomics-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-28T20:05:00.000Z NeoGenomics Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/CHRS/coherus-tagmokitug-esophageal-cancer-data BiopharmaWatch en 2026-10-28T20:05:00.000Z Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development https://www.biopharmawatch.com/news/CBLL/ceribell-participate-canaccord-genuity-medtech-diagnostics-digital-health-services-forum BiopharmaWatch en 2026-10-28T20:05:00.000Z Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-kol-event-nf1-treatment BiopharmaWatch en 2026-10-28T20:05:00.000Z Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026 https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-q3-2026-results-conference-call BiopharmaWatch en 2026-10-28T20:05:00.000Z Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026 https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-10-28T20:05:00.000Z Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/PGEN/precigen-announces-q3-2026-results-call BiopharmaWatch en 2026-10-28T20:05:00.000Z Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4 https://www.biopharmawatch.com/news/TDOC/teladoc-health-reports-q3-2026-results BiopharmaWatch en 2026-10-28T20:05:00.000Z Teladoc Health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/MDXG/mimedx-third-quarter-2026-results BiopharmaWatch en 2026-10-28T20:03:00.000Z MIMEDX Announces Third Quarter 2026 Operating & Financial Results https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-name-change-azora-therapeutics BiopharmaWatch en 2026-10-28T20:02:00.000Z Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-10-28T20:01:00.000Z Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-579-phase-1-results BiopharmaWatch en 2026-10-28T20:01:00.000Z Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026 https://www.biopharmawatch.com/news/MDXG/mimedx-patent-license-agreement-25-million BiopharmaWatch en 2026-10-28T20:01:00.000Z MIMEDX Announces $25 Million Patent License Agreement https://www.biopharmawatch.com/news/SPRY/ars-pharma-third-quarter-2026-results BiopharmaWatch en 2026-10-28T20:01:00.000Z ARS Pharma to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MLAB/mesa-labs-second-quarter-results-2026 BiopharmaWatch en 2026-10-28T20:00:00.000Z Mesa Labs Announces Second Quarter Financial Results Release Date and Earnings Conference Call